CEL-SCI Corp (CVM)

2.39
0.06 2.40
AMEX : Health Care
Prev Close 2.45
Open 2.35
Day Low/High 2.35 / 2.48
52 Wk Low/High 0.36 / 0.80
Volume 82.37K
Avg Volume 214.10K
Exchange AMEX
Shares Outstanding 9.19M
Market Cap 22.62M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CEL-SCI Announces New Data For Its Rheumatoid Arthritis Vaccine Candidate Published In Peer Reviewed Journal

CEL-SCI Corporation (NYSE MKT: CVM) announces the publication of data from rheumatoid arthritis (RA) studies in Vaccine, a leading peer-reviewed journal for researchers interested in vaccines and vaccination.

CEL-SCI Extends The Expiration Date Of Series DD Warrants Issued In December 2016

CEL-SCI Corporation (NYSE MKT: CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from June 8, 2017 to July 10, 2017 (close of business).

CEL-SCI Submits FDA Response For Its Phase 3 Head And Neck Cancer Trial

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has responded to the U.

CEL-SCI Corporation Releases Letter To Shareholders

The following letter is being released by CEL-SCI Corporation (NYSE MKT:CVM) to its shareholders: Dear Fellow Shareholders: We are giving you an update on clinical hold communications with the U.

CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Daniel Zimmerman, Ph.

CEL-SCI Announces Change To The Date Of Its Annual Meeting

CEL-SCI Corporation (NYSE MKT: CVM) today announced it has changed the date for its annual meeting from June 9, 2017 to June 12, 2017.

CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2017.

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.

CEL-SCI Announces $1.51 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with one institutional investor for an offering of shares of common stock with gross proceeds of approximately $1.

CEL-SCI Receives Intent To Grant Notice For New Multikine Patent From The European Patent Office

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has been notified that it will be granted a new patent on Multikine* (Leukocyte Interleukin, Injection), its investigational cancer immunotherapy, from the...

CEL-SCI Corporation Releases Letter To Shareholders

The following letter is being released by CEL-SCI Corporation (NYSE MKT: CVM) to its shareholders: Dear Fellow Shareholders: Our Phase 3 study in advanced primary (untreated) head and neck cancer...

CEL-SCI Scientist Presents At The World Vaccine Congress

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Dr.

CEL-SCI Announces $1.5 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $1.

CEL-SCI Gives Update On Partial Clinical Hold On Phase 3 Head And Neck Cancer Study With Multikine

CEL-SCI Corporation (NYSE MKT: CVM) announces that it has received the official minutes from its February 8, 2017 meeting with the U.

CEL-SCI Announces That The NYSE MKT Approves Plan

CEL-SCI Corporation (NYSE MKT: CVM) announces that the NYSE MKT (the "Exchange") has accepted the Company's plan to bring itself into compliance with the Exchange's continued listing standards.

CEL-SCI Scientist Presents New Findings For Rheumatoid Arthritis Treatment Vaccine At Conference

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Dr.

CEL-SCI Announces $1.0 Million Registered Direct Offering

CEL-SCI Corporation (NYSE MKT:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $1.

CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2016.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CEL-SCI Announces Closing Of Public Offereing And Receives Audit Opinion With Going Concern Explanation

CEL-SCI Announces Closing Of Public Offereing And Receives Audit Opinion With Going Concern Explanation

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL-SCI" or the "Company") announced today that it has received net proceeds of $3,702,760 and expects to receive the remaining $75,000 this week from its previously announced public...

CEL-SCI Reports Fiscal 2016 Financial Results And Clinical & Corporate Developments

CEL-SCI Reports Fiscal 2016 Financial Results And Clinical & Corporate Developments

CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") reported financial results today for the fiscal year ended September 30, 2016.

CEL-SCI Reports On NYSE MKT Noncompliance Notice And Compliance Plan

CEL-SCI Reports On NYSE MKT Noncompliance Notice And Compliance Plan

CEL-SCI Corporation (NYSE MKT: CVM) reported on a communication received today from the staff of the NYSE MKT, its current listing exchange, that it considered the Company to be noncompliant with certain listing...

CEL-SCI Announces Pricing Of $4.25 Million Public Offering Of Common Stock And Warrants

CEL-SCI Announces Pricing Of $4.25 Million Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has priced its public offering of common stock and warrants.

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Announces Proposed Public Offering Of Common Stock And Warrants

CEL-SCI Corporation (NYSE MKT: CVM) announced today that it intends to offer and sell, subject to market and other conditions shares of its common stock and warrants to purchase common stock.

CEL-SCI Submits Response To FDA In Connection With Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Submits Response To FDA In Connection With Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has submitted its response to the U.

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating Rheumatoid Arthritis

CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, today announced new...

CEL-SCI Provides Update On Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Provides Update On Partial Clinical Hold On Phase 3 Clinical Trial

CEL-SCI Corporation (NYSE MKT:CVM) announced today: following up on our press release issued on September 26, 2016, we have received the Partial Clinical Hold letter from the U.